137 related articles for article (PubMed ID: 36867178)
1. Aripiprazole Augmentation in Older Persons with Treatment-Resistant Depression.
Lewis G; Lewis G
N Engl J Med; 2023 Mar; 388(12):1137-1138. PubMed ID: 36867178
[No Abstract] [Full Text] [Related]
2. Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
Gebara MA; DiNapoli EA; Kasckow J; Karp JF; Blumberger DM; Lenze EJ; Mulsant BH; Reynolds CF
Int J Geriatr Psychiatry; 2018 Feb; 33(2):e330-e335. PubMed ID: 28975710
[TBL] [Abstract][Full Text] [Related]
3. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
[TBL] [Abstract][Full Text] [Related]
4. Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial.
Hsu JH; Mulsant BH; Lenze EJ; Sanches M; Karp JF; Reynolds CF; Blumberger DM
J Clin Psychiatry; 2018 Jun; 79(4):. PubMed ID: 29924506
[TBL] [Abstract][Full Text] [Related]
5. Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports.
Arandjelovic K; Eyre HA; Lavretsky H
Am J Geriatr Psychiatry; 2016 Oct; 24(10):913-7. PubMed ID: 27591914
[TBL] [Abstract][Full Text] [Related]
6. Some augmentation strategies improve outcome but increase discontinuation in adults with treatment-resistant depression.
Andrade C
Evid Based Ment Health; 2016 May; 19(2):e7. PubMed ID: 27208385
[No Abstract] [Full Text] [Related]
7. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S; Johnson GR; Sevilimedu V; Rao SD; Hicks PB; Chen P; Lauro K; Jurjus G; Pilkinton P; Davis L; Wilcox JA; Iranmanesh A; Sapra M; Aslam M; Michalets J; Thase M; Zisook S;
J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32603560
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized.
Cristancho P; Lenard E; Lenze EJ; Miller JP; Brown PJ; Roose SP; Montes-Garcia C; Blumberger DM; Mulsant BH; Lavretsky H; Rollman BL; Reynolds CF; Karp JF
Am J Geriatr Psychiatry; 2019 Oct; 27(10):1138-1152. PubMed ID: 31147244
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
Chen SJ; Hsiao YL; Shen TW; Chen ST
J Clin Psychopharmacol; 2012 Feb; 32(1):56-60. PubMed ID: 22198444
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
[TBL] [Abstract][Full Text] [Related]
11. The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
Bartova L; Fugger G; Dold M; Kautzky A; Swoboda MMM; Rujescu D; Zohar J; Souery D; Mendlewicz J; Montgomery S; Fabbri C; Serretti A; Kasper S
Int J Neuropsychopharmacol; 2022 Feb; 25(2):118-127. PubMed ID: 34637516
[TBL] [Abstract][Full Text] [Related]
12. Augmentation With Aripiprazole or Bupropion, or a Switch to Nortriptyline, Effective for Treatment-Resistant Depression in Older Adults.
Ebell MH
Am Fam Physician; 2023 Sep; 108(3):Online. PubMed ID: 37725473
[No Abstract] [Full Text] [Related]
13. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.
Yoshimura R; Kishi T; Hori H; Ikenouchi-Sugita A; Katsuki A; Umene-Nakano W; Iwata N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):355-7. PubMed ID: 22813840
[TBL] [Abstract][Full Text] [Related]
14. Lamotrigine augmentation therapy in a case with treatment-resistant unipolar depression that showed insufficient response to electroconvulsive therapy.
Mihara K; Nakamura A; Nemoto K; Nagai G; Kagawa S; Suzuki T; Kondo T
Psychiatry Clin Neurosci; 2016 Feb; 70(2):126. PubMed ID: 26661501
[No Abstract] [Full Text] [Related]
15. Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder.
Kamijima K; Yasuda M; Yamamura K; Fukuta Y
Curr Med Res Opin; 2018 Dec; 34(12):2105-2112. PubMed ID: 30173568
[TBL] [Abstract][Full Text] [Related]
16. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole augmentation treatment in treatment resistant bipolar depression: two patient reports.
Karadağ F; Tan D; Unal F
Turk Psikiyatri Derg; 2011; 22(4):269-72. PubMed ID: 22143953
[TBL] [Abstract][Full Text] [Related]
18. Treatment-resistant depressive disorders: The when, how and what of augmentation therapy.
Bassett D; Parker G; Hamilton A; Morris G; Baune BT; Boyce P; Hopwood M; Mulder R; Porter R; Singh A; Outhred T; Mannie Z; Das P; Malhi GS
Aust N Z J Psychiatry; 2019 Mar; 53(3):187-189. PubMed ID: 30722673
[No Abstract] [Full Text] [Related]
19. What are the comparative benefits and harms of augmentation treatments in major depression?
Shelton RC
J Clin Psychiatry; 2015 Apr; 76(4):e531-3. PubMed ID: 25919851
[TBL] [Abstract][Full Text] [Related]
20. General Predictors and Moderators of Depression Remission: A VAST-D Report.
Zisook S; Johnson GR; Tal I; Hicks P; Chen P; Davis L; Thase M; Zhao Y; Vertrees J; Mohamed S
Am J Psychiatry; 2019 May; 176(5):348-357. PubMed ID: 30947531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
